STAT3 and neoplasm: Our results showed that in all six patients, p-STAT3 in αSMA+ CAFs were only detectable in tumor sections post-PARPi treatment, but not in patient-matched biopsies taken before PARPi therapy (Figure 3D and Supplementary Figure S6).